Lasting response after discontinuation of cemiplimab in a patient with locally advanced basal cell carcinoma.

Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. However, when HPIs fail or are no longer tolerated due to HPI-induced adverse events, options for further treatment are limited: the only way to proceed is with some form of treatment via clinical trials or palliative therapies. Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. [Extracted from the article]